4507:TYO
Shionogi
JP¥ 2.769,00
0,00%
(0,00) 1D
8 okt, 15:30:00 GMT+9 · JPY
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor 4507 genereren…
Beursw.
2,37Â bln.
Gem. vol.
2,93Â mln.
Volume
0,00
Dividend
2,56%
Kwartaaldividend
JP¥ 18
Ex-dividenddatum
29 sep 2026
Koers/winst-verhouding
8,94
52 wk hoog
JP¥ 3.758
52 wk laag
JP¥ 2.392
WPA
JP¥ 310
Uitstaande aandelen
314,50Â mln.
Aantal medewerkers
6K
Beursw.
2,37Â bln.
Gem. vol.
2,93Â mln.
Volume
0,00
Dividend
2,56%
Kwartaaldividend
JP¥ 18
Ex-dividenddatum
29 sep 2026
Koers/winst-verhouding
8,94
52 wk hoog
JP¥ 3.758
52 wk laag
JP¥ 2.392
WPA
JP¥ 310
Uitstaande aandelen
314,50Â mln.
Aantal medewerkers
6K
Nieuwsartikelen
Van webbronnen en nieuwspartners
Nikkei Asia
·
3 dagen geleden
Shionogi to buy US-based IntraBio for $2bn to expand rare disease drug business
Fierce Pharma
·
3 dagen geleden
Shionogi strikes $2B deal for IntraBio hot off FDA label expansion
Profiel
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Over Shionogi